{'fraction_non_alphanumeric': 0.013230429988974642, 'fraction_numerical': 0.007717750826901874, 'mean_word_length': 5.485714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Current management of facial neuroma

Since their initial description in 1930, more than 400 facial neuromas have been reported in the world literature. Relative to secondary neoplastic involvement of the facial nerve, primary neurogenic tumors of the facial nerve remain relatively uncommon. The diagnostic challenge lies in the lack of uniformity in clinical presentation of these tumors and their ability to mimic other benign entities occurring within the same anatomic location. Surgical excision offers the only option for curative treatment. Because tumor removal almost always necessitates segmental resection of the facial nerve with subsequent neural repair, long-term residual facial paresis is an expected outcome of surgery. For this reason, timing of surgery and the role of surgical decompression remain controversial. This review outlines the basis for current management of facial neuromas.